Real-world sites of care and patient characteristics associated with subcutaneous versus intravenous nivolumab treatment in the United States (ESMO-IO 2026) - Oct 25, 2026 - Abstract #200P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Clinical • Real-world • Real-world evidence • Oncology
|
|
Roxana Dronca; Joanna Boland; Ella Du; Keith A. B etts; Andriy Moshyk; Eileen Han
|